SAKAR HEALTHCARE LIMITED Fair Value
SAKAR · Healthcare · Current price ₹991
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹136 | 6% ROE fading to 12% over ~3 yrs, on ₹146 book |
| Relative P/E | ₹536 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹212 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,020 | Street consensus 12-month target price |
Is SAKAR HEALTHCARE LIMITED undervalued?
DocStoX estimates the fair value of SAKAR HEALTHCARE LIMITED at ₹397 per share, versus the current market price of ₹991. That puts the stock about -60.0% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹136), Relative P/E (₹536), Graham floor (₹212), Analyst target (₹1,020). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹136 (bear) to ₹397 (base) to ₹1,020 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on SAKAR HEALTHCARE LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.